Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. 8-K earnings release, 10-Q stay in one workspace.
ATRA
$9.25
-1.60%
ATRA
· Atara Biotherapeutics, Inc.
$9.25
-0.15 (-1.60%)
At close · Oct 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our existing cash, cash equivalents and short-term investments as of June 30, 2026 will not be sufficient to fund our planned operations for at least the next twelve months from the date of issuance of these financial statements. These conditions raise substantial doubt about our ability to continue as a going concern for at least 12 months after the issuance of the accompanying condensed consolidated financial statements.”View the 10-Q filed Aug 12, 2026
Market Cap
$82.31M
Shares
10.04M
Volume · Oct 5
39.32K
Avg daily vol (3M)
57.61K
All webcasts
Earnings call · FY2020 Q3
Atara Biotherapeutics, Inc. (ATRA) Q3 2020 Earnings Call
Research coverage
2 live sources
Open each available source without leaving this research workspace.
Net income
-$74.35M
Research materials
Open the source you need; every reader stays inside this workspace.
SEC filing · Item 2.02
8-K earnings release
Filed Nov 9, 2020 · complete as-filed document
SEC periodic report
10-Q report
Filed Nov 9, 2020 · complete as-filed document